Advertisement

Current Transplantation Reports

, Volume 5, Issue 4, pp 273–281 | Cite as

State of the Science in Deceased Organ Donor Management

  • Madhukar S. Patel
  • Mitchell Sally
  • Claus U. Niemann
  • Darren J. Malinoski
Anesthesia and Critical Care in Transplantation (D Axelrod and M Kaufman, Section Editors)
  • 24 Downloads
Part of the following topical collections:
  1. Topical Collection on Anesthesia and Critical Care in Transplantation

Abstract

Purpose of Review

Research in deceased organ donor management offers an opportunity to increase the quantity and quality of organs available for transplantation. This article aims to appraise the current literature with a focus on reviewing deceased donor intervention trials.

Recent Findings

Aggressive critical care management after determination of brain death resulting in meeting of a donor management goal bundle has consistently demonstrated an association with significantly more organs transplanted per donor as well as improved graft outcomes. Although there is a dearth of experience with randomized donor intervention studies, dopamine and targeted mild therapeutic hypothermia have been found to significantly reduce delayed graft function in kidney recipients.

Summary

Progress in understanding the ethical, legal, regulatory, policy, and organizational elements of organ donor research has provided a mechanism that allows for the endorsement of potentially impactful donor management studies. Ongoing trials should incorporate methods to ensure safety to all organs donated from donors enrolled in interventional trials.

Keywords

Deceased organ donor Organ donor management Donor intervention research Organ donor clinical trial 

Notes

Funding Information

This work was supported in part by the Health Resources and Services Administration contract 234-2005-37011C. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.

Compliance with Ethical Standards

Conflict of Interest

Madhukar Patel, Mitchell Sally, and Claus Niemann declare no conflict of interest. Darren Malinoski reports grants from the Laura and John Arnold Foundation, during the conduct of the study.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. 1.
    McKeown DW, Bonser RS, Kellum JA. Management of the heartbeating brain-dead organ donor. Br J Anaesth. 2012;108(Suppl 1):i96–107.PubMedCrossRefGoogle Scholar
  2. 2.
    •• Kotloff RM, Blosser S, Fulda GJ, Malinoski D, Ahya VN, Angel L, et al. Management of the potential organ donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement. Crit Care Med. 2015;43(6):1291–325. Consensus statement providing practical recommendations to aid critical care practitioners in the management of potential organ donors. PubMedCrossRefGoogle Scholar
  3. 3.
    Malinoski DJ, Patel MS, Ahmed O, Daly MC, Mooney S, Graybill CO, et al. The impact of meeting donor management goals on the development of delayed graft function in kidney transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2013;13(4):993–1000.CrossRefGoogle Scholar
  4. 4.
    Malinoski DJ, Patel MS, Daly MC, Oley-Graybill C, Salim A. The impact of meeting donor management goals on the number of organs transplanted per donor: results from the United Network for Organ Sharing Region 5 prospective donor management goals study. Crit Care Med. 2012;40(10):2773–80.PubMedCrossRefGoogle Scholar
  5. 5.
    Malinoski DJ, Daly MC, Patel MS, Oley-Graybill C, Foster CE 3rd, Salim A. Achieving donor management goals before deceased donor procurement is associated with more organs transplanted per donor. J Trauma. 2011;71(4):990–5. discussion 6PubMedCrossRefGoogle Scholar
  6. 6.
    Franklin GA, Santos AP, Smith JW, Galbraith S, Harbrecht BG, Garrison RN. Optimization of donor management goals yields increased organ use. Am Surg. 2010;76(6):587–94.PubMedGoogle Scholar
  7. 7.
    Westphal GA. A simple bedside approach to therapeutic goals achievement during the management of deceased organ donors--an adapted version of the “VIP” approach. Clin Transpl. 2016;30(2):138–44.CrossRefGoogle Scholar
  8. 8.
    • Patel MS, De La Cruz S, Sally MB, Groat T, Malinoski DJ. Active donor management during the hospital phase of care is associated with more organs transplanted per donor. J Am Coll Surg. 2017;225(4):525–31. Prospective observational study demonstrating a substantial increase in organs transplanted per donor with active critical care of the potential organ donor. PubMedCrossRefGoogle Scholar
  9. 9.
    Critical Pathway for the Organ Donor [Available from: https://www.unos.org/wp-content/uploads/unos/Critical_Pathway.pdf.
  10. 10.
    Malinoski DJ, Patel MS, Lush S, Willis ML, Navarro S, Schulman D, et al. Impact of compliance with the American College of Surgeons trauma center verification requirements on organ donation-related outcomes. J Am Coll Surg. 2012;215(2):186–92.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Malinoski DJ, Daly MC, Patel MS, Oley-Graybill C, Foster CE 3rd, Salim A. Achieving donor management goals before deceased donor procurement is associated with more organs transplanted per donor. J Trauma. 2011;71(4):990–5. discussion 6PubMedCrossRefGoogle Scholar
  12. 12.
    •• Souter MJ, Blissitt PA, Blosser S, Bonomo J, Greer D, Jichici D, et al. Recommendations for the critical care management of devastating brain injury: prognostication, psychosocial, and ethical management : a position statement for healthcare professionals from the Neurocritical Care Society. Neurocrit Care. 2015;23(1):4–13. Position statement to help guide management during the first 72 h after devastating brain injury. PubMedCrossRefGoogle Scholar
  13. 13.
    Abt PL, Marsh CL, Dunn TB, Hewitt WR, Rodrigue JR, Ham JM, et al. Challenges to research and innovation to optimize deceased donor organ quality and quantity. Am J Transplant. 2013;13(6):1400–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Feng S. Donor intervention and organ preservation: where is the science and what are the obstacles? Am J Transplant. 2010;10(5):1155–62.PubMedCrossRefGoogle Scholar
  15. 15.
    •• Niemann CU, Feiner J, Swain S, Bunting S, Friedman M, Crutchfield M, et al. Therapeutic hypothermia in deceased organ donors and kidney-graft function. N Engl J Med. 2015;373(5):405–14. Randomized controlled trial demonstrating the impact of therapeutic hypotermia in the decased organ donor on signficantly decreasing delayed kidney graft function in recipients. PubMedCrossRefGoogle Scholar
  16. 16.
    Rodrigue JR, Feng S, Johansson AC, Glazier AK, Abt PL. Deceased donor intervention research: a survey of transplant surgeons, organ procurement professionals, and institutional review board members. Am J Transplant. 2016;16(1):278–86.PubMedCrossRefGoogle Scholar
  17. 17.
    Glazier AK, Heffernan KG, Rodrigue JR. A framework for conducting deceased donor research in the United States. Transplantation. 2015;99(11):2252–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Mone T, Heldens J, Niemann CU. Deceased organ donor research: the last research frontier? Liver Transpl. 2013;19(2):118–21.PubMedCrossRefGoogle Scholar
  19. 19.
    •• National Academies of Sciences E, Medicine. Opportunities for organ donor intervention research: saving lives by improving the quality and quantity of organs for transplantation. In: Childress JF, Domnitz S, Liverman CT, editors. . Washington, DC: The National Academies Press; 2017. 220 p. Report discussing the ethical, legal, regulatory, policy, and organizational elements of organ donor research, and endorsing the need for further coordination and design of donor intervention studies. Google Scholar
  20. 20.
    Koneru B, Shareef A, Dikdan G, Desai K, Klein KM, Peng B, et al. The ischemic preconditioning paradox in deceased donor liver transplantation-evidence from a prospective randomized single blind clinical trial. Am J Transplant. 2007;7(12):2788–96.PubMedCrossRefGoogle Scholar
  21. 21.
    Bongu A, Washburn WK, Oliver JB, Davidow AL, Nespral J, Pentakota SR, et al. Remote ischemic preconditioning in neurological death organ donors: the RIPNOD Prospective Randomized Clinical Trial. J Am Coll Surg. 2017;225(4):e171.CrossRefGoogle Scholar
  22. 22.
    Schnuelle P, Mundt HM, Druschler F, Schmitt WH, Yard BA, Kramer BK, et al. Impact of spontaneous donor hypothermia on graft outcomes after kidney transplantation. Am J Transplant. 2018;18(3):704–14.Google Scholar
  23. 23.
    •• Schnuelle P, Schmitt WH, Weiss C, Habicht A, Renders L, Zeier M, et al. Effects of dopamine donor pretreatment on graft survival after kidney transplantation: a randomized trial. Clin J Am Soc Nephrol. 2017;12(3):493–501. Five-year follow-up of renal transplant patients participating in dopamine donor pretreatment clinical trial showing no signficant graft survival advanatage on intention-to-treat analysis but noting an exposure-response relationship which may provide advanatage to a subset. PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Benck U, Hoeger S, Brinkkoetter PT, Gottmann U, Doenmez D, Boesebeck D, et al. Effects of donor pre-treatment with dopamine on survival after heart transplantation: a cohort study of heart transplant recipients nested in a randomized controlled multicenter trial. J Am Coll Cardiol. 2011;58(17):1768–77.PubMedCrossRefGoogle Scholar
  25. 25.
    Schnuelle P, Gottmann U, Hoeger S, Boesebeck D, Lauchart W, Weiss C, et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA. 2009;302(10):1067–75.PubMedCrossRefGoogle Scholar
  26. 26.
    Benck U, Gottmann U, Hoeger S, Lammert A, Rose D, Boesebeck D, et al. Donor desmopressin is associated with superior graft survival after kidney transplantation. Transplantation. 2011;92(11):1252–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Schnuelle P, Benck U, Yard BA. Dopamine in transplantation: written off or comeback with novel indication? Clin Transpl. 2018:e13292.Google Scholar
  28. 28.
    Brinkkoetter PT, Song H, Losel R, Schnetzke U, Gottmann U, Feng Y, et al. Hypothermic injury: the mitochondrial calcium, ATP and ROS love-hate triangle out of balance. Cell Physiol Biochem. 2008;22(1–4):195–204.PubMedCrossRefGoogle Scholar
  29. 29.
    Mascia L, Pasero D, Slutsky AS, Arguis MJ, Berardino M, Grasso S, et al. Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial. JAMA. 2010;304(23):2620–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Ware LB, Landeck M, Koyama T, Zhao Z, Singer J, Kern R, et al. A randomized trial of the effects of nebulized albuterol on pulmonary edema in brain-dead organ donors. Am J Transplant. 2014;14(3):621–8.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Orban JC, Quintard H, Cassuto E, Jambou P, Samat-Long C, Ichai C. Effect of N-acetylcysteine pretreatment of deceased organ donors on renal allograft function: a randomized controlled trial. Transplantation. 2015;99(4):746–53.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    D’Amico F, Vitale A, Piovan D, Bertacco A, Ramirez Morales R, Chiara Frigo A, et al. Use of N-acetylcysteine during liver procurement: a prospective randomized controlled study. Liver Transpl. 2013;19(2):135–44.PubMedCrossRefGoogle Scholar
  33. 33.
    Yarlagadda SG, Coca SG, Formica RN Jr, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant. 2009;24(3):1039–47.PubMedCrossRefGoogle Scholar
  34. 34.
    Butala NM, Reese PP, Doshi MD, Parikh CR. Is delayed graft function causally associated with long-term outcomes after kidney transplantation? Instrumental variable analysis. Transplantation. 2013;95(8):1008–14.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    McLaren AJ, Jassem W, Gray DW, Fuggle SV, Welsh KI, Morris PJ. Delayed graft function: risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. Clin Transpl. 1999;13(3):266–72.CrossRefGoogle Scholar
  36. 36.
    Tapiawala SN, Tinckam KJ, Cardella CJ, Schiff J, Cattran DC, Cole EH, et al. Delayed graft function and the risk for death with a functioning graft. J Am Soc Nephrol. 2010;21(1):153–61.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Fonseca I, Teixeira L, Malheiro J, Martins LS, Dias L, Castro Henriques A, et al. The effect of delayed graft function on graft and patient survival in kidney transplantation: an approach using competing events analysis. Transpl Int. 2015;28(6):738–50.PubMedCrossRefGoogle Scholar
  38. 38.
    Gill J, Dong J, Rose C, Gill JS. The risk of allograft failure and the survival benefit of kidney transplantation are complicated by delayed graft function. Kidney Int. 2016;89(6):1331–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Lee J, Song SH, Lee JY, Kim DG, Lee JG, Kim BS, et al. The recovery status from delayed graft function can predict long-term outcome after deceased donor kidney transplantation. Sci Rep. 2017;7(1):13725.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Troppmann C, Gillingham KJ, Benedetti E, Almond PS, Gruessner RW, Najarian JS, et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis. Transplantation. 1995;59(7):962–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Al-Khafaji A, Murugan R, Wahed AS, Lebovitz DJ, Souter MJ, Kellum JA, et al. Monitoring Organ Donors to Improve Transplantation Results (MOnIToR) trial methodology. Crit Care Resusc. 2013;15(3):234–40.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Al-Khafaji A, Elder M, Lebovitz DJ, Murugan R, Souter M, Stuart S, et al. Protocolized fluid therapy in brain-dead donors: the multicenter randomized MOnIToR trial. Intensive Care Med. 2015;41(3):418–26.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Niemann CU, Broglio K, Malinoski D. Comments on “Impact of spontaneous donor hypothermia on graft outcomes after kidney transplantation”. Am J Transplant. 2018;18(3):763.PubMedCrossRefGoogle Scholar
  44. 44.
    Koneru B, Fisher A, He Y, Klein KM, Skurnick J, Wilson DJ, et al. Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy. Liver Transpl. 2005;11(2):196–202.PubMedCrossRefGoogle Scholar
  45. 45.
    Raza A, Dikdan G, Desai KK, Shareef A, Fernandes H, Aris V, et al. Global gene expression profiles of ischemic preconditioning in deceased donor liver transplantation. Liver Transpl. 2010;16(5):588–99.PubMedGoogle Scholar
  46. 46.
    Desai KK, Dikdan GS, Shareef A, Koneru B. Ischemic preconditioning of the liver: a few perspectives from the bench to bedside translation. Liver Transpl. 2008;14(11):1569–77.PubMedCrossRefGoogle Scholar
  47. 47.
    Sharpe MD, van Rassel B, Haddara W. Oral and intravenous thyroxine (T4) achieve comparable serum levels for hormonal resuscitation protocol in organ donors: a randomized double-blinded study. Can J Anaesth. 2013;60(10):998–1002.PubMedCrossRefGoogle Scholar
  48. 48.
    Ware LB, Koyama T, Billheimer D, Landeck M, Johnson E, Brady S, et al. Advancing donor management research: design and implementation of a large, randomized, placebo-controlled trial. Ann Intensive Care. 2011;1(1):20.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Orban JC, Fontaine E, Cassuto E, Baumstarck K, Leone M, Constantin JM, et al. Effects of cyclosporine A pretreatment of deceased organ donors on kidney graft function (Cis-A-rein): study protocol for a randomized controlled trial. Trials. 2018;19(1):231.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Robertson FP, Magill LJ, Wright GP, Fuller B, Davidson BR. A systematic review and meta-analysis of donor ischaemic preconditioning in liver transplantation. Transpl Int. 2016;29(11):1147–54.PubMedCrossRefGoogle Scholar
  51. 51.
    Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74(5):1124–36.PubMedCrossRefGoogle Scholar

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2018

Authors and Affiliations

  • Madhukar S. Patel
    • 1
  • Mitchell Sally
    • 2
    • 3
  • Claus U. Niemann
    • 4
    • 5
  • Darren J. Malinoski
    • 2
    • 3
  1. 1.Department of SurgeryMassachusetts General HospitalBostonUSA
  2. 2.Surgical Critical Care SectionPortland Veterans Affairs Medical CenterPortlandUSA
  3. 3.Department of SurgeryOregon Health & Science UniversityPortlandUSA
  4. 4.Department of Anesthesia and Perioperative CareUniversity of California San FranciscoSan FranciscoUSA
  5. 5.Department of Surgery, Division of TransplantationUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations